Expanded Access Program for R007 (Probucol) Tablets in Adults With Mitochondrial Disease and Chronic Kidney Disease

NCT ID: NCT06931834

Last Updated: 2025-04-17

Basic Information

• Recruitment Status: AVAILABLE
• Study Classification: EXPANDED_ACCESS

Brief Summary

The purpose of this expanded access program is to enable access to R007 (probucol) tablets for the compassionate treatment of adults with mitochondrial disease who also have chronic kidney disease.

Detailed Description

The protocol for this expanded access program provides for the compassionate treatment with R007 (probucol) tablets of adults who (i) have serious or life-threatening mitochondrial disease and also have chronic kidney disease stages 3 or 4, (ii) do not have access to a satisfactory alternative therapy to treat their condition, and (iii) are not able to enroll in a clinical trial.

Conditions

Mitochondrial Disease; Chronic Kidney Disease

Interventions

Probucol

Probucol 250 mg tablets orally up to a daily dose of 1,000 mg

Intervention Type: DRUG

Other Intervention Names

R007; Lorelco

Eligibility Criteria

Inclusion Criteria

A patient must meet all of the following criteria to be eligible:

1. Age 18 to 75 years inclusive;

2. Diagnosis of genetically-confirmed mitochondrial disease with a pathogenic mutation or defect in their mitochondrial or nuclear DNA;

3. Diagnosis of chronic kidney disease stage 3 or stage 4;

4. Moderate or severe symptomatology of mitochondrial disease;

5. A sexually-active patient agrees to practice acceptable methods of contraception throughout the protocol period;

6. The patient is not eligible for, or does not have access to, a clinical trial;

7. The patient (or guardian/legal representative) provides signed and dated informed consent to be treated with probucol in accordance with the expanded access protocol.

Exclusion Criteria

A patient who meets any of the following criteria will not be eligible:

1. A known hypersensitivity or adverse reaction to probucol;

2. A medical condition or laboratory result that, in the opinion of the treating physician, will interfere with the safe completion of the protocol;

3. An active fungal infection, acute blood, lung, or bladder infection, clinically significant hepatic or renal dysfunction, and/or viral infection (past or present) that, in the opinion of the treating physician, may have a clinically significant effect on their treatment;

4. Taking an investigational drug other than probucol within one month prior to the first dosing with probucol under the protocol;

5. A medical history or condition that increases the potential for QTc prolongation;

6. A female with a positive pregnancy test result or who is breastfeeding;

7. Has received or is receiving kidney dialysis;

8. Has received or is scheduled to receive an organ transplant;

9. Known or suspected active alcohol and/or substance abuse;

10. A history of or current suicidal ideation, behavior, and/or attempts; or

11. Is unable to swallow tablets or requires gastric feeding.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Children's Hospital of Philadelphia

OTHER

Sponsor Role: collaborator

RiboNova Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Zarazuela Zolkipli-Cunningham, MBChB

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital of Philadelphia

Locations

The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status: AVAILABLE

Countries

United States

Central Contacts

Zarazuela Zolkiplki-Cunningham, MBChB

Role: CONTACT

MMFP@chop.edu

267-426-4961

Sara Nguyen, MPH

Role: CONTACT

MMFP@CHOP.edu

267-426-1986

Facility Contacts

Zarazuela Zolkipli-Cunningham, MBChB

Role: primary

MMFP@chop.edu

267-426-4961

Sara Nguyen, MPH

Role: backup

MMFP@chop.edu

267-426-1986

Other Identifiers

EP2025010101

Identifier Type: -

Identifier Source: org_study_id